Industry voices including Tia Harmon at PHCNA are spotlighting real‑time metabolic monitoring technologies that deliver earlier intervention points in complex cell and gene therapy (CGT) workflows. These platforms provide continuous readouts of cell health and metabolism during manufacturing runs, enabling rapid corrective actions that can raise yield and consistency for autologous and allogeneic products. For GMP-scale CGT manufacturing, tighter process control reduces batch failures and speeds tech‑transfer; vendors and CDMOs should expect growing demand for inline metabolic analytics. Adoption will hinge on demonstrated regulator-accepted data packages and integration into existing manufacturing control strategies.